Quality Care 2019: Does Comprehensive Genomic Profiling Improve Outcomes in Metastatic Kidney Cancer?
Posted: Monday, September 30, 2019
Knowledge of a patient’s genomic alterations may guide treatment and contribute to improved overall survival in metastatic renal cell carcinoma, according to a poster presented at the 2019 American Society of Clinical Oncology (ASCO) Quality Care Symposium (Abstract 63) by Paulo Gustavo Bergerot, MD, of City of Hope National Medical Center in California, and colleagues.
“This study provides preliminary evidence to justify comprehensive genomic profiling–guided therapy in metastatic renal cell carcinoma,” wrote the authors.
The investigators identified 64 patients with metastatic renal cell carcinoma from a single institution who had underwent comprehensive genomic profiling. They excluded 15 patients from the analysis because of either no follow-up data, or death or hospice treatment within 30 days, for a total of 49 patients. Of the patients included in the analysis, 69% had clear cell renal cell carcinoma, and 79% were male.
The patients’ genomic profiling results indicated that 47% (23 patients) had actionable mutations. Of those patients, 13 were treated with directed therapy, resulting in stable disease for 57%, partial response for 28%, and progressive disease for 14% . The median duration of directed therapy, measured in months between the first and last days of therapy, was 12 months, and the median duration of nondirected therapy was 4 months. Directed therapy was associated with better overall survival (hazard ratio = 0.32) than nondirected therapy. Further prospective studies are needed to validate these results.
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.